The purpose of this study is to determine the preference of RA patients for the new Enbrel® (etanercept) pre-filled syringe in patients who are already taking Enbrel®.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• > 18 years at the screening baseline visit
• Have established RA diagnosis as determined by ACR criteria
• Be current user of etanercept-lyophilized preparation for at least 4 consecutive weeks of etanercept dosing on either a once weekly or twice weekly regimen
• Subject must be able to self inject
• Give written informed consent

Exclusion Criteria:

• Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s)
• Subject of childbearing potential is pregnant (e.g., positive HCG test) or is breast-feeding
• Elective surgery is planned during study period
• Subjects allergic to latex